- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research
This guidance provides firms with information on the appropriate electronic file format to use when electronically submitting to FDA postmarket, non-expedited individual case safety reports (ICSRs) on adverse drug experiences. Non-expedited ICSRs are the case reports required to be submitted at the time firms submit their periodic adverse (drug) experience reports (21 CFR 314.80(c)(2)(ii)(b) and 600.80(c)(2)(ii)(B)). This guidance explains that firms that previously submitted non-expedited ICSRs in an electronic format that is not supported by FDA should contact the Center for Drug Evaluation and Research (CDER)3 or the Center for Biologics Evaluation and Research (CBER) and resubmit their non-expedited ICSRs in a compatible electronic format.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2013-D-0755.